Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the Hemostatus

Thrombosis Research

Volumn 95, Issue 2, 1999, Pages 83-91

  Coiffic, Alain ^a   Cazes, Eric ^a   Janvier, Gérard ^a   Forestier, François ^a   Lanza, François ^b   Nurden, Alan ^a   Nurden, Paquita ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b Etablissement de Transfus Sanguine   (France)

Author keywords

Activated clotting time; Hemostatus; Monitoring platelet function

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; KAOLIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; FIBRIN FORMATION; GLANZMANN DISEASE; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE ANOMALY; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ASPIRIN; BLOOD COAGULATION TESTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBASTHENIA; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 0033565442     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00034-1     Document Type: Article

References (30)

1. Woodman R.C., Harker L.A. Bleeding complication associated with cardiopulmonary bypass. Blood. 76:1990;1680-1697.
2. Edmunds L.H. Platelet function during and after ECC in cardiac surgery. RBM. 18:1993;231-232.
3. Rodgers C.R.P., Levin J. A critical reappraisal of the bleeding time. Sem Thromb Haemost. 16:1990;1-20.
4. Despotis G.J., Levine V., Filos K.S., Santoro S.A., Joist J.H., Spitznagel E., Goodnough L.T. Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology. 85:1996;1311-1323.
5. Ereth M.H., Nutall G.A., Klindworth J.T., MacVeigh I., Santrach P.J., Orszulak T.H., Harmsen W.S., Oliver W.C. Does the platelet-activated clotting test (Hemostatus) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg. 85:1997;259-264.
6. Bold J. Acute platelet mild plasmapheresis for cardiac surgery. J Cardiothorac Vasc Anesth. 9:1995;79-88.
7. Goodnough L.T., Soegiarso R.W., Birkmeyer J.D., Welch H.G. Economic impact of inappropriate blood transfusion in coronary artery bypass graft surgery. Am J Med. 94:1993;509-514.
8. Wong C.A., Franklin M.L., Wade L.D. Coagulation test, blood loss, and transfusion requirements in platelet-rich plasmapheresed versus nonpheresed cardiac surgery patients. Anesth Analg. 78:1994;29-36.
9. Ray M.J., Hawson G.A.T., Just S.J., Mac Lachlan G., O'Brien M. Relationship of platelet aggregation to bleeding after cardiopulmonary bypass. Ann Thorac Surg. 57:1994;981-986.
10. Horrow J. Management of coagulation and bleeding disorders. Kaplan J.A. Cardiac Anesthesia. 1993;957-958 W. L. Saunders, Philadelphia.
11. Topol E.J. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am Heart J. 130:1995;667-672.
12. The EPIC Investigators Use of monoclonal antibody directed against the platelet glycoprotein IIb-IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
13. Tcheng J.E. Glycoprotein IIb/IIIa receptor inhibitors. Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective Am J Cardiol. 78:1996;35-40.
14. George J.N., Caen J.P., Nurden A.T. Glanzmann's thrombasthenia. The spectrum of clinical disease Blood. 75:1990;1383-1395.
15. Ruggeri Z.M. Glycoprotein Ib and von Willebrand factor in the process of thrombus formation. Ann NY Acad Sci. 714:1994;200-210.
16. De La Salle C., Lanza F., Cazenave J.-P. Biochemical and molecular basis of Bernard-Soulier syndrome. A review Nouv Rev Fr Hematol. 37:1995;215-222.
17. Kestin A.S., Ellis P.A., Barnard M.R., Errichetti A., Rosner B.A., Michelson A.D. Effect of strenuous exercise on platelet activation state and reactivity. Circulation. 88:1993;1502-1511.
18. Despotis G.J., Ikonomakou S., Levine V., Joiner-Maier D., Santoro S.A., Joist J.H. Effects of platelets and with blood cells and antiplatelet agent c7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood. Thromb Res. 86:1997;205-219.
19. Ammar T., Fisher C.F., Sarier K., Coller B.S. The effects of thrombocytopenia on the activated coagulation time. Anesth Analg. 83:1996;1185-1188.
20. Ereth M.H., Nuttall G.A., Santrach P.J., Klindworth J.T., Oliver W.C., Schaff H.V. The relation between the platelet-activated clotting test (Hemostatus) and blood loss after cardiopulmonary bypass. Anesthesiology. 88:1998;962-969.
21. Koltai M., Hosford D., Braquet P. Role of PAF and cytokines in microvascular tissue injury. J Lab Clin Med. 119:1992;461-466.
22. Hynes R.O. Integrins. A family of cell surface receptor Cell. 48:1987;548-554.
23. Nurden A.T., Nurden P. A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. Ballières Clin Haematol. 6:1993;653-690.
24. Nurden P. Bidirectional trafficking of membrane glycoproteins following platelet activation in suspension. Thromb Haemost. 78:1997;1305-1315.
25. Moliterno D.J., Califf R.M., Aguirre F.V., Anderson K., Sigmon K.N., Weisman H.F., Topol E. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol. 75:1995;559-562.
26. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis" J Clin Invest. 98:1996;863-874.
27. 3 binds prothrombin and influences its activation. J Biol Chem. 272:1997;27183-27188.
28. Nurden P., Poujol C., Durrieu-Jais C., Winckler J., Combrie R., Macchi L., Bihour C., Wagner C., Jordan R., Nurden A.T. Labeling of the internal Pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab, ReoPro). Flow and endocytic mechanisms contribute to the transport Blood. 93:1999;1622-1633.
29. Fressinaud E., Veyradier A., Truchaud F., Martin I., Boyer-Neumann C., Trossaert M., Meyer D. Screening for von Willebrand disease with a new analyzer using high shear stress. A study of 60 cases Blood. 91:1998;1325-1331.
30. Poujol C., Nurden A.T., Paponeau A., Heilmann E., Nurden P. Ultrastructural analysis of the distribution of von Willebrand factor and fibrinogen in platelet aggregates formed in the PFA-100™ Platelets. 9:1998;381-389.